BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Resverlogix Corporation (RVX.TO)' RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials


4/23/2012 10:05:23 AM

This Novel Epigenetic Mechanism Defines an Entirely New Class of Therapeutic

TSX Exchange Symbol: RVX

CALGARY, April 23, 2012 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announces the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production. Our data shows RVX-208 to be an inhibitor of the Bromodomain and Extraterminal Domain (BET) proteins. RVX-208 acts on BET proteins, including BRD4, a member of the BET-protein family, leading to increased transcription of the ApoA-I gene followed by production of more ApoA-I protein.

ApoA-I is the major protein component of HDL, a class of lipoproteins believed to reduce atherosclerosis through reverse cholesterol transport (RCT). The ability of RVX-208 to increase ApoA-I makes it the lead candidate in Resverlogix' pipeline for treating atherosclerotic cardiovascular disease. RVX-208 is an orally active small molecule, the first in a new class of compounds to enter into human clinical trials more than 4 years ago. Clinical benefits of RVX-208 are currently being explored in two concurrent Phase 2b clinical trials (SUSTAIN and ASSURE), led by Cleveland Clinic.

"The finding that RVX-208 inhibits BET proteins is an important discovery for a wide scientific and medical audience," stated Dr. Norman Wong, Chief Scientific Officer of Resverlogix. "This discovery is important because BET proteins are key players in 'epigenetics', a critical mechanism for regulating the expression of genes. Epigenetic processes are mediated by proteins, including the BET-proteins, that act in concert with the DNA to make it transcriptionally active or dormant. This epigenetic control of gene expression plays a key role in the development and progression of many human diseases. The knowledge gained from studies of RVX-208 will guide Resverlogix in its search for additional compounds to treat some of these diseases," added Dr. Wong.

"The MoA of RVX-208 has allowed the company to expand the scope of its technology and the potential of its pipeline significantly," stated Donald McCaffrey, President and Chief Executive Officer of Resverlogix. "We have been generating and filing new intellectual property since our discovery, and see the opportunity to initiate licensing and partnering discussions in the areas of atherosclerosis, oncology, autoimmune and Alzheimer's diseases where the MoA plays a pivotal role." Mr. McCaffrey added that, "the value of this discovery was further validated when Dr. James Watson, in his first solo scientific publication since 1972, highlighted the promise of BRD4 as a therapeutic target and in particular, against untreatable cancers."

As previously announced, Resverlogix will be hosting a Conference Call and Webcast today, April 23, 2012, commencing at 11 am EDT to present in further detail the Mechanism of Action of RVX-208.

Link to access the Webcast:
http://services.choruscall.com/links/resverlogix120423.html

Conference call dial-in numbers:
Canada & USA Toll Free Dial In: 1-800-319-4610
Outside of Canada & USA call: +1-604-638-5340

Epigenetics
Epigenetics is the study of processes that enable information encoded in DNA to be expressed. Although DNA encodes the genes, by itself DNA cannot use this data. To use the data within DNA, it must work in concert with proteins. An essential aspect in this collaborative process is that both DNA and proteins are packaged together into chromosomes that reside within the cell's nucleus. There are thousands of different genes encoded within DNA and to enable expression of these genes when called upon by the cell requires epigenetic processes. One of the key epigenetic processes involves modification of chromosomal proteins by acetylation, methylation or phosphorylation, each of which is regulated by specific enzymes. These modified entities serve as bait for other proteins including BET proteins to bind to or so called "read" these modifications ("the epigenetic code"). As the BET proteins bind, they recruit additional proteins to regulate gene activity. When the gene becomes active, it leads to synthesis of messenger ribonucleic acid (mRNA) followed by translation of mRNA into a specific protein. In the past decade, tremendous progress has been made in understanding the role of epigenetics in human disease. This in depth understanding has led to the development of medicines directed toward cancer, such as DNA methylation inhibitors and HDAC inhibitors. The discovery that RVX-208 is a BET bromodomain inhibitor adds new momentum to the promise of epigenetic mechanisms as a rich source of new medicines.

RVX-208
RVX-208 is a novel small molecule that stimulates endogenous ApoA-I production to trigger the synthesis of HDL. The use of this approach will enhance the functionality of HDL. ApoA-I is the major protein component of HDL. The main role of these particles is to act as the body's natural defense system against atherosclerosis by mediating a normal physiologic process called reverse cholesterol transport (RCT). This pathway enables cholesterol, including that within atherosclerotic plaques of vessel walls, to be transported to the liver for further processing and elimination from the body. Enhanced RCT clearance of cholesterol from vessel walls is expected to reduce or prevent atherosclerosis. The ability of RVX-208 to increase ApoA-I production and thereby augment RCT differentiates it from other HDL therapies. RVX-208 is positioned to be one of the most promising drugs in development for the treatment of atherosclerosis.

Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas technology platform is the Company's primary focus, developing novel small molecules that enhance ApoA-I production. These vital therapies are focused on addressing the burden of Atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease, Oncology and Autoimmune diseases. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Company Contacts:
Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: don@resverlogix.com
Sarah Zapotichny
Director of Investor Relations
Resverlogix Corp.
Phone: 403-254-9252
Email: sarah@resverlogix.com
US Institutional Investors: Media:
Susan Noonan
Managing Partner
S.A. Noonan Communications, LLC
Phone: 212-966-3650
Email: susan@sanoonan.com

Tony Russo, Ph.D.
Matt Middleman, M.D.
Russo Partners, LLC
Phone: 212 845 4251
Phone: 212-845-4272
Email: tony.russo@russopartnersllc.com
Email: matt.middleman@russopartnersllc.com

SOURCE Resverlogix Corp.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->